


PENDING

(IN202311003264)

Dual-port in-memory computing static random-access- memory (SRAM) macro



NEED

Traditional drug delivery systems face challenges with achieving controlled, sustained release of active ingredients, leading to suboptimal therapeutic outcomes. What if drug release could be managed more effectively?

TECHNOLOGY OVERVIEW

This invention presents a gelling composition using albumin and an organic solvent to enable sustained release of active ingredients. The composition can be tailored for bioactive compounds, enhancing the controlled delivery of therapeutic agents over extended periods.

TECHNOLOGY KEY FEATURES

1) Sustained release of active ingredients. 2) Use of albumin in the aqueous phase for gel strength. 3) Incorporates water-miscible organic solvents like ethanol or NMP. 4) Customizable for hydrophobic and hydrophilic active ingredients.

[Read more here](#)

MARKET ANALYSIS

The global sustained release drug delivery market is projected to grow at a CAGR of 9.2% from 2023 to 2033, driven by increasing demand for controlled drug release in chronic diseases. (Source: Grand View Research, 2023)

Target Industries

1) Pharmaceutical companies developing long-acting injectable drugs. 2) Biotech firms specializing in nanoformulations for targeted drug delivery. 3) Healthcare providers looking for controlled release formulations to improve patient compliance.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913